Most Active Stocks in Pre-Market Trading on October 1, 2025: LAC, RZLV, TSLL, AES, ASST, SQQQ, IONZ, NVDA, NIO, NKE, NVO, PFE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 01 2025
0mins
Should l Buy NVO?
Source: NASDAQ.COM
NASDAQ 100 Pre-Market Performance: The NASDAQ 100 Pre-Market Indicator is down by 118.01 points, with a total volume of approximately 137 million shares traded.
Active Stocks Overview: Lithium Americas Corp. (LAC) shows significant trading activity with a 165.75% increase over its target price, while other notable stocks include Rezolve AI PLC (RZLV) in the "buy range" and NVIDIA Corporation (NVDA) experiencing a decline after reaching a 52-week high.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 40.810
Low
42.00
Averages
54.67
High
70.00
Current: 40.810
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics: A Potential Obesity Market Leader
- Surging Market Demand: The obesity treatment sector is experiencing explosive demand, with projections suggesting a market size nearing $100 billion by the decade's end, positioning Viking Therapeutics as a potential beneficiary of significant revenue opportunities.
- Clinical Trial Progress: Viking's VK2735 injectable is currently in phase 3 trials, having completed enrollment ahead of schedule, indicating strong patient interest; successful trial outcomes could pave the way for commercialization and revenue generation.
- Competitive Edge: As a GLP-1 class drug, Viking's candidate could provide a competitive alternative to existing products from Lilly and Novo, potentially capturing market share and generating substantial income if it successfully enters the market.
- Investment Return Potential: Although Viking has yet to achieve profitability, its stock surged 121% on positive phase 2 news, highlighting its volatility; continued positive developments could yield significant returns for investors in the future.
See More
Viking Therapeutics Targets Billion-Dollar Obesity Market
- Clinical Trial Progress: Viking Therapeutics' VK2735 injectable is currently in a phase 3 trial that completed enrollment ahead of schedule, indicating strong market demand for this potential new drug, which could secure a foothold in the obesity drug market if successful.
- Massive Market Potential: The obesity drug market is projected to approach $100 billion by 2030, and if Viking's products are successfully commercialized, the company could capture a significant share of this lucrative market, driving substantial growth.
- Competitive Landscape Analysis: With Eli Lilly and Novo Nordisk currently dominating the market, Viking's promising clinical candidates could generate considerable revenue if they reach commercialization, thereby enhancing the company's competitive position.
- Investor Attention: Although Viking's stock surged 121% in early 2024 due to positive news, caution is warranted as investors should closely monitor the ongoing developments in its obesity program to assess long-term investment potential.
See More
Novo Nordisk Plans to Add 2,000 Employees Amid Restructuring
- Hiring Initiative: Novo Nordisk plans to add approximately 2,000 employees in 2025, with 1,400 already onboard, including nearly 400 in Denmark, despite facing a 5% voluntary attrition rate and an overall turnover rate nearing 18%.
- Restructuring Context: Under new CEO Mike Doustdar, the company underwent significant restructuring in 2025, cutting about 7,800 roles, or 10% of its workforce, indicating deep changes even at senior levels.
- Recruitment vs. Attrition: This hiring push is more about filling gaps created by layoffs rather than team expansion, highlighting the challenges and opportunities the company faces in its recovery process.
- Future Outlook: While the hiring initiative appears positive, the company must still tackle the challenges posed by high turnover rates to ensure that new hires can effectively integrate into the team and drive sustained growth.
See More
CNBC Investing Club April Meeting Highlights
- Market Rebound Analysis: The S&P 500 index reached a record high in April, marking a significant recovery from the Iran war sell-off, indicating a renewed focus on company fundamentals despite the ongoing conflict, which underscores the importance of investor calmness.
- Nike Investment Reflection: Despite insider buying signals prompting us to increase our stake in Nike last December, we are now skeptical about CEO Elliott Hill's ability to turn the company around, and if next quarter's performance is disappointing, we will consider exiting.
- Amazon Cloud Business Recovery: Amazon's stock rebound highlights the importance of patience, as the market is gradually recognizing the strength of its AWS cloud division and online retail business, which are expected to continue growing in the future.
- Nvidia Market Leadership: Nvidia's leading position in the AI chip sector is paying off, and despite competitive pressures, its advantage in computing power positions it well to maintain market leadership going forward.
See More
Investment Comparison: CVS Health vs. Novo Nordisk
- Diversification Advantage: CVS Health, through its Aetna subsidiary, is one of the largest health insurers in the U.S., and while diversification may spread resources thin, it is expected to benefit in the long run as demand for medical products and services increases.
- Market Leadership: CVS Health's leadership in various healthcare niches, supported by strong relationships with patients, doctors, and payers, positions it well to navigate regulatory barriers and market challenges effectively.
- Concentration Risks for Novo Nordisk: Novo Nordisk's focus on metabolic diseases has made it a leader in the diabetes drug market, but its declining competitiveness in the weight loss market and recent clinical setbacks could significantly worsen its financial results.
- Investment Outlook Comparison: Although Novo Nordisk's stock has declined significantly over the past two years, its deep pipeline in weight loss could lead to recovery in the coming years, making both companies attractive options for long-term investors.
See More
Novo Nordisk Expands Workforce by 2,000 Amid Restructuring
- Workforce Expansion: Novo Nordisk has added approximately 2,000 employees year-to-date, including nearly 400 in Denmark, reflecting successful talent acquisition during its restructuring, although this does not necessarily indicate a net increase in total headcount.
- Attrition Rate Insights: The company currently has a voluntary attrition rate of about 5%, projected to rise to 18% by 2025, indicating potential challenges in managing human resources as employee turnover may increase post-restructuring.
- Historical Layoff Impact: By the end of 2025, Novo Nordisk's total headcount stood at 69,505, down approximately 7,800 from the previous year, marking a 10% reduction, which is the largest layoff in the company's history, affecting several executives including the co-inventor of liraglutide.
- Executive Changes: During the restructuring, Chief Scientific Officer's chief advisor Lotte Bjerre Knudsen announced her departure after a 36-year tenure, a decision made collaboratively with management, highlighting the company's focus on talent mobility amid restructuring efforts.
See More
Viking Therapeutics: A Potential Obesity Market Leader
- Surging Market Demand: The obesity treatment sector is experiencing explosive demand, with projections suggesting a market size nearing $100 billion by the decade's end, positioning Viking Therapeutics as a potential beneficiary of significant revenue opportunities.
- Clinical Trial Progress: Viking's VK2735 injectable is currently in phase 3 trials, having completed enrollment ahead of schedule, indicating strong patient interest; successful trial outcomes could pave the way for commercialization and revenue generation.
- Competitive Edge: As a GLP-1 class drug, Viking's candidate could provide a competitive alternative to existing products from Lilly and Novo, potentially capturing market share and generating substantial income if it successfully enters the market.
- Investment Return Potential: Although Viking has yet to achieve profitability, its stock surged 121% on positive phase 2 news, highlighting its volatility; continued positive developments could yield significant returns for investors in the future.
See More
Viking Therapeutics Targets Billion-Dollar Obesity Market
- Clinical Trial Progress: Viking Therapeutics' VK2735 injectable is currently in a phase 3 trial that completed enrollment ahead of schedule, indicating strong market demand for this potential new drug, which could secure a foothold in the obesity drug market if successful.
- Massive Market Potential: The obesity drug market is projected to approach $100 billion by 2030, and if Viking's products are successfully commercialized, the company could capture a significant share of this lucrative market, driving substantial growth.
- Competitive Landscape Analysis: With Eli Lilly and Novo Nordisk currently dominating the market, Viking's promising clinical candidates could generate considerable revenue if they reach commercialization, thereby enhancing the company's competitive position.
- Investor Attention: Although Viking's stock surged 121% in early 2024 due to positive news, caution is warranted as investors should closely monitor the ongoing developments in its obesity program to assess long-term investment potential.
See More
Novo Nordisk Plans to Add 2,000 Employees Amid Restructuring
- Hiring Initiative: Novo Nordisk plans to add approximately 2,000 employees in 2025, with 1,400 already onboard, including nearly 400 in Denmark, despite facing a 5% voluntary attrition rate and an overall turnover rate nearing 18%.
- Restructuring Context: Under new CEO Mike Doustdar, the company underwent significant restructuring in 2025, cutting about 7,800 roles, or 10% of its workforce, indicating deep changes even at senior levels.
- Recruitment vs. Attrition: This hiring push is more about filling gaps created by layoffs rather than team expansion, highlighting the challenges and opportunities the company faces in its recovery process.
- Future Outlook: While the hiring initiative appears positive, the company must still tackle the challenges posed by high turnover rates to ensure that new hires can effectively integrate into the team and drive sustained growth.
See More
CNBC Investing Club April Meeting Highlights
- Market Rebound Analysis: The S&P 500 index reached a record high in April, marking a significant recovery from the Iran war sell-off, indicating a renewed focus on company fundamentals despite the ongoing conflict, which underscores the importance of investor calmness.
- Nike Investment Reflection: Despite insider buying signals prompting us to increase our stake in Nike last December, we are now skeptical about CEO Elliott Hill's ability to turn the company around, and if next quarter's performance is disappointing, we will consider exiting.
- Amazon Cloud Business Recovery: Amazon's stock rebound highlights the importance of patience, as the market is gradually recognizing the strength of its AWS cloud division and online retail business, which are expected to continue growing in the future.
- Nvidia Market Leadership: Nvidia's leading position in the AI chip sector is paying off, and despite competitive pressures, its advantage in computing power positions it well to maintain market leadership going forward.
See More
Investment Comparison: CVS Health vs. Novo Nordisk
- Diversification Advantage: CVS Health, through its Aetna subsidiary, is one of the largest health insurers in the U.S., and while diversification may spread resources thin, it is expected to benefit in the long run as demand for medical products and services increases.
- Market Leadership: CVS Health's leadership in various healthcare niches, supported by strong relationships with patients, doctors, and payers, positions it well to navigate regulatory barriers and market challenges effectively.
- Concentration Risks for Novo Nordisk: Novo Nordisk's focus on metabolic diseases has made it a leader in the diabetes drug market, but its declining competitiveness in the weight loss market and recent clinical setbacks could significantly worsen its financial results.
- Investment Outlook Comparison: Although Novo Nordisk's stock has declined significantly over the past two years, its deep pipeline in weight loss could lead to recovery in the coming years, making both companies attractive options for long-term investors.
See More
Novo Nordisk Expands Workforce by 2,000 Amid Restructuring
- Workforce Expansion: Novo Nordisk has added approximately 2,000 employees year-to-date, including nearly 400 in Denmark, reflecting successful talent acquisition during its restructuring, although this does not necessarily indicate a net increase in total headcount.
- Attrition Rate Insights: The company currently has a voluntary attrition rate of about 5%, projected to rise to 18% by 2025, indicating potential challenges in managing human resources as employee turnover may increase post-restructuring.
- Historical Layoff Impact: By the end of 2025, Novo Nordisk's total headcount stood at 69,505, down approximately 7,800 from the previous year, marking a 10% reduction, which is the largest layoff in the company's history, affecting several executives including the co-inventor of liraglutide.
- Executive Changes: During the restructuring, Chief Scientific Officer's chief advisor Lotte Bjerre Knudsen announced her departure after a 36-year tenure, a decision made collaboratively with management, highlighting the company's focus on talent mobility amid restructuring efforts.
See More
